News | October 27, 2014

Minimally Invasive Procedures Offer Hope for Elderly Patients with Heart-Valve Problems

TAVR proves effective for patients at University of Texas Southwestern Medical Center

Werner Dyer, who is now 92, had his TAVR last year and was able to rejoin his bowling league and now bowls four times a week.

October 27, 2014 – Annie Henderson, 69, suffers from multiple chronic ailments, including kidney failure and mitral valve insufficiency. The latter turned her life into a battle for breath, eliminating almost all activities and even making sleep a struggle. She couldn’t sleep for more than 20 minutes at a time without waking in a fit of coughing. Thanks to a leading-edge procedure performed at University of Texas (UT) Southwestern Medical Center, Mrs. Henderson is now breathing – and sleeping – easy.

UT Southwestern physicians perform two types of minimally invasive valve-repair procedures that offer hope for patients like Mrs. Henderson, who have incapacitating heart-valve problems but are too frail to undergo the rigors of open-heart surgeries. 

Transcatheter aortic valve replacement (TAVR) is used to replace a critically narrowed aortic valve, the valve between the heart and the main artery in the body. TAVR patients’ narrowed aortic valves prevent sufficient blood flow. The TAVR procedure is a less invasive treatment, alleviating the narrowing without the need for open-heart surgery.

The procedure involving the MitraClip device repairs a valve between the upper and lower chambers of the left side of the heart, called the mitral valve. This valve may not close fully, causing blood to flow backward into the left atrium and lungs. The MitraClip pinches the two leafs of the mitral valve together in the center so there is less backflow of blood.

Both procedures are performed by snaking catheters, typically from a blood vessel in the groin, up to the diseased valve. Patients may experience immediate improvement, and since the only incision is a small one to allow access to the blood vessel, recovery time is short.

This summer, UT Southwestern physicians performed their 50th TAVR procedure and, recently, Sarah Gualano, M.D., assistant professor of internal medicine and medical director of the Cardiac Catheterization Laboratory, with Michael Luna, M.D., assistant professor of internal medicine, performed the first MitraClip procedures. Mrs. Henderson was one of the first MitraClip patients.   

Gualano said she has seen patients whose lives had become restricted because of their heart-valve problems re-emerging into a wider world after their procedures.

“I had a patient in his 90s who could barely walk a block, doing calisthenics in his room after his TAVR procedure. Werner Dyer, who is now 92, had his TAVR last year and was able to rejoin his bowling league and now bowls four times a week.”

“It boils down to the simple fact that these patients had no options, and now we can make them feel better and, in the case of TAVR, live longer,” said Gualano.

Demographics mean these procedures will be increasingly important in the coming years.

“We have an aging population. As people age, they become very high-risk for open-heart surgeries,” said Steven Marso, M.D., medical director of interventional cardiology and professor of internal medicine. “People who wouldn’t have had an option for treatment now have an option for treatment,” he said.

Sitting in her hospital room 36 hours after her MitraClip procedure, Mrs. Henderson was beaming. Breathing is the easy process it should be once again, and there had been no coughing the previous night. “I didn’t wake up until the nurse woke me this morning,” Mrs. Henderson said happily.

For more information:

Related Content

ACC Launches Transcatheter Valve Certification
News | Heart Valve Technology | March 14, 2019
March 14, 2019 — Beginning in mid-2019, hospitals performing...
FDA Approves MitraClip for Use in Heart Failure Patients With Functional Mitral Regurgitation
Feature | Heart Valve Technology | March 14, 2019 | Jeff Zagoudis, Associate Editor
March 14, 2019 — The U.S.
Scientists Discover New Type of Immune Cells Essential for Forming Heart Valves

Microscopic images of a normal heart valve in a mouse, left, and a heart valve grown in a lab with heart-derived macrophages blocked, right. Without those macrophages, the valves are thick and deformed. Image courtesy of Developmental Cell/UCLA Broad Stem Cell Research Center.

News | Heart Valve Technology | March 06, 2019
UCLA researchers have identified for the first time the origin of an immune cell that plays a critical role in the...
Global Market for Transcatheter Treatments to Double in Next Five Years
News | Heart Valve Technology | March 01, 2019
When it comes to treatment options for a damaged heart valve, nothing is getting more attention than transcatheter...
FDA Approves IDE Study for Foldax Biopolymer Heart Valve Platform
News | Heart Valve Technology | February 18, 2019
Foldax Inc. announced the U.S. Food and Drug Administration (FDA) has granted investigative device exemption (IDE)...
Thubrikar Announces First-in-Human Implant of Optimum TAVI System
News | Heart Valve Technology | January 29, 2019
Thubrikar Aortic Valve Inc. announced the first human implant of the Optimum TAV using their transcatheter aortic valve...
Perceval Valve Offers Performance, Economic Advantages in Aortic Disease Treatment
News | Heart Valve Technology | January 29, 2019
LivaNova PLC announced the publication of three separate studies highlighting the performance of its sutureless aortic...
First Tendyne Transcatheter Mitral Valve Implanted in New York
News | Heart Valve Technology | January 28, 2019
Lenox Hill Hospital is the first hospital in New York City to successfully implant Abbott’s Tendyne transcatheter...
Overlay Init